AXA Parenterals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: AXA Parenterals Limited Pharmaceutical Export Portfolio Dataset — 10 Products, $2.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AXA Parenterals Limited — Pharmaceutical Exporter Profile (2026) | 10 Products, $2.2M Trade | TransData Nexus

AXA Parenterals Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $2.2M Total Trade · DGFT Verified

AXA Parenterals Limited is an Indian pharmaceutical exporter with a total trade value of $2.2M across 10 products in 5 therapeutic categories. Based on 88 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Budesonide ($1.0M), Linezolid ($325.8K), Fludarabine ($250.0K).

AXA Parenterals Limited — Export Portfolio & Destination Treemap

AXA Parenterals Limited pharmaceutical export portfolio — 10 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is AXA Parenterals Limited? — Company Overview & Market Position

AXA Parenterals Limited, established on July 22, 2005, is a public unlisted company headquartered in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24232DL2005PLC148247. Its authorized capital stands at ₹7.5 crore, with a paid-up capital of ₹7.38 crore. AXA Parenterals specializes in the manufacturing and marketing of sterile parenteral preparations, life-saving medicines, and hospital products. The company's operations are active, and it has a significant presence in both domestic and international markets.

The registered office of AXA Parenterals Limited is located at 703-704, Pearls Best Height-2, Netaji Subhash Place, Pitampura, Delhi, 110034, India. The company operates under the Ministry of Corporate Affairs (MCA) and is classified as a non-government company limited by shares. AXA Parenterals has been actively involved in the pharmaceutical sector for over two decades, focusing on the production of high-quality parenteral formulations.

What Does AXA Parenterals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Budesonide$1.0M 2

Product Portfolio — Top 10 by Export Value

AXA Parenterals Limited exports 10 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Budesonide	Respiratory	$1.0M	43	0.5%	6
2	Linezolid	Advanced Antibiotics	$325.8K	9	0.9%	14
3	Fludarabine	Advanced Oncology	$250.0K	5	8.7%	2
4	Etanercept	Biologics & Immunotherapy	$200.0K	4	0.3%	2
5	Ipratropium	Respiratory	$141.7K	6	0.2%	13
6	Mitomycin	Advanced Oncology	$88.4K	3	1.1%	7
7	Ifosfamide	Advanced Oncology	$65.0K	3	2.7%	7
8	Dacarbazine	Advanced Oncology	$47.4K	7	3.3%	8
9	Vinblastine	Oncology	$37.1K	5	4.9%	5
10	Nilotinib	Advanced Oncology	$1.2K	3	0.1%	7

AXA Parenterals Limited exports 10 pharmaceutical products across 5 therapeutic categories with a total export value of $2.2M. The top category is Respiratory (53.3% of portfolio), followed by Advanced Oncology (20.8%), indicating a concentrated portfolio with the top 5 products accounting for 89.0% of total export value.

AXA Parenterals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

AXA Parenterals Limited operates a state-of-the-art manufacturing facility located in Roorkee, Uttarakhand, India. The plant is designed in accordance with US FDA and EU guidelines, ensuring compliance with stringent regulatory standards. The facility spans 145,000 square feet of land, with a constructed area of 280,000 square feet over two floors. This expansive setup enables the company to produce a wide range of sterile parenteral preparations, including large and small volume parenterals, infusions, ophthalmic preparations, respiratory products, and critical care medicines.

The manufacturing plant is equipped with advanced technology and adheres to Good Manufacturing Practices (GMP) to ensure the highest quality standards. The facility's design and operations are aligned with the requirements of regulated markets, reflecting AXA Parenterals' commitment to excellence in pharmaceutical manufacturing.

3Key Leadership

AXA Parenterals Limited is led by a team of experienced professionals committed to driving the company's growth and maintaining its reputation for quality. The key executives include:

Manoj Agarwal: Co-founder and Director, appointed on August 16, 2005.

Puneet Kansal: Director, appointed on October 10, 2005.

Sumit Kumar Agarwal: Director, appointed on October 1, 2010.

Ruchir Gupta: Director, appointed on October 1, 2010.

Avinash Chander Kher: Director, appointed on November 1, 2016.

Milap Kapoor: Director, appointed on November 1, 2016.

Yasha Agarwal: Whole-time Director, appointed on January 1, 2023.

This leadership team brings a wealth of experience and expertise to AXA Parenterals, guiding the company towards continued success in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does AXA Parenterals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

AXA Parenterals Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility is accredited with WHO-GMP certification, ensuring compliance with international quality standards. Additionally, AXA Parenterals has applied for EU-GMP certification, demonstrating its commitment to meeting the stringent requirements of the European market.

The company's adherence to US FDA and EU guidelines reflects its dedication to producing high-quality pharmaceutical products suitable for these regulated markets. AXA Parenterals' focus on compliance with international standards positions it as a reliable supplier in these regions. The company's products are designed to meet the specific regulatory requirements of each market, ensuring safety and efficacy for patients worldwide.

2Emerging Markets

AXA Parenterals Limited has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP accreditation facilitates access to these regions, as it meets the quality standards recognized by the World Health Organization. This accreditation enables AXA Parenterals to supply its products to countries that require WHO-GMP certification for pharmaceutical imports.

In Africa, AXA Parenterals has established a strong presence, supplying life-saving medicines and hospital products to various countries. In Latin America, the company has penetrated markets such as Brazil and Colombia, offering a range of pharmaceutical products. In Southeast Asia, AXA Parenterals has expanded its footprint in countries like Thailand, the Philippines, and Singapore, providing high-quality parenteral formulations. The company's commitment to quality and compliance with international standards has been instrumental in its success in these emerging markets.

AXA Parenterals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

AXA Parenterals Limited's manufacturing facility is designed to comply with US FDA guidelines, reflecting the company's commitment to meeting the stringent requirements of the US market. The facility's adherence to these standards ensures that the company's products are suitable for export to the United States. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available, the company's compliance with US FDA guidelines indicates a strong foundation for potential market access.

The company's focus on meeting US FDA standards positions it to explore opportunities in the US market, contingent upon obtaining the necessary regulatory approvals. AXA Parenterals' commitment to quality and compliance enhances its prospects for successful entry into the US pharmaceutical market.

2WHO & EU GMP

AXA Parenterals Limited holds WHO-GMP accreditation, demonstrating its adherence to international quality standards recognized by the World Health Organization. The company has also applied for EU-GMP certification, indicating its commitment to meeting the stringent requirements of the European market. These certifications reflect AXA Parenterals' dedication to producing high-quality pharmaceutical products suitable for regulated markets.

Frequently Asked Questions — AXA Parenterals Limited

How many pharmaceutical products does AXA Parenterals Limited export from India?

AXA Parenterals Limited exports 10 pharmaceutical products across 5 therapeutic categories. The top exports are Budesonide ($1.0M), Linezolid ($325.8K), Fludarabine ($250.0K), Etanercept ($200.0K), Ipratropium ($141.7K). Total export value is $2.2M.

What is AXA Parenterals Limited's total pharmaceutical export value?

AXA Parenterals Limited's total pharmaceutical export value is $2.2M, based on 88 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does AXA Parenterals Limited cover?

AXA Parenterals Limited exports across 5 therapeutic categories. The largest are Respiratory (53.3%, 2 products), Advanced Oncology (20.8%, 5 products), Advanced Antibiotics (15.0%, 1 products).

Get Full AXA Parenterals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.